Pub Date : 2024-12-01DOI: 10.1016/j.jaccao.2024.08.007
Santino Butler MD , Hyunsoo No MD , Felicia Guo BA , Gibran Merchant BS , Natalie J. Park BA , Scott Jackson MS , Daniel Eugene Clark MD , Lucas Vitzthum MD , Alex Chin MD, MBA , Kathleen Horst MD , Richard T. Hoppe MD , Billy W. Loo MD, PhD , Maximilian Diehn MD, PhD , Michael Sargent Binkley MD, MS
Background
Atrial fibrillation (AF) has been associated with thoracic radiotherapy, but the specific risk with irradiating different cardiac substructures remains unknown.
Objectives
This study sought to examine the relationship between irradiation of cardiac substructures and the risk of clinically significant (grade ≥3) AF.
Methods
We analyzed data from patients who underwent definitive radiotherapy for localized cancers (non–small cell lung, breast, Hodgkin lymphoma, or esophageal) at our institution between 2004 and 2022. The 2-Gy fraction equivalent dose was calculated for cardiac substructures, including the pulmonary veins (PVs), left atrium, sinoatrial node, and left coronary arteries (the left main, left anterior descending, and left circumflex arteries). Competing risk models (subdistribution HRs [sHRs]) for AF incidence were adjusted for the Mayo AF risk score (MAFRS).
Results
Among 539 patients, the median follow-up was 58.8 months. The 5-year cumulative incidence of AF was 11.1% for non–small cell lung cancer, 8.3% for esophageal cancer, 1.3% for breast cancer, and 0.8% for Hodgkin lymphoma. Increased AF risk was associated with a higher PV maximum dose (dmax) (sHR: 1.22; P < 0.001), larger left atrial volume (sHR: 1.01; P = 0.002), greater smoking history in pack-years (sHR: 1.01; P = 0.010), and higher MAFRS (sHR: 1.16; P < 0.001). PV dmax remained a significant predictor of AF across different MAFRS subgroups (Pinteraction = 0.11), and a PV dmax >39.7 Gy was linked to a higher AF risk, even when stratified by MAFRS.
Conclusions
PV dmax is a significant predictor of grade ≥3 AF regardless of underlying risk factors. These findings highlight the importance of cardiac substructures in radiation toxicity and suggest that various PV dose metrics should be further validated in clinical settings.
{"title":"Predictors of Atrial Fibrillation After Thoracic Radiotherapy","authors":"Santino Butler MD , Hyunsoo No MD , Felicia Guo BA , Gibran Merchant BS , Natalie J. Park BA , Scott Jackson MS , Daniel Eugene Clark MD , Lucas Vitzthum MD , Alex Chin MD, MBA , Kathleen Horst MD , Richard T. Hoppe MD , Billy W. Loo MD, PhD , Maximilian Diehn MD, PhD , Michael Sargent Binkley MD, MS","doi":"10.1016/j.jaccao.2024.08.007","DOIUrl":"10.1016/j.jaccao.2024.08.007","url":null,"abstract":"<div><h3>Background</h3><div>Atrial fibrillation (AF) has been associated with thoracic radiotherapy, but the specific risk with irradiating different cardiac substructures remains unknown.</div></div><div><h3>Objectives</h3><div>This study sought to examine the relationship between irradiation of cardiac substructures and the risk of clinically significant (grade ≥3) AF.</div></div><div><h3>Methods</h3><div>We analyzed data from patients who underwent definitive radiotherapy for localized cancers (non–small cell lung, breast, Hodgkin lymphoma, or esophageal) at our institution between 2004 and 2022. The 2-Gy fraction equivalent dose was calculated for cardiac substructures, including the pulmonary veins (PVs), left atrium, sinoatrial node, and left coronary arteries (the left main, left anterior descending, and left circumflex arteries). Competing risk models (subdistribution HRs [sHRs]) for AF incidence were adjusted for the Mayo AF risk score (MAFRS).</div></div><div><h3>Results</h3><div>Among 539 patients, the median follow-up was 58.8 months. The 5-year cumulative incidence of AF was 11.1% for non–small cell lung cancer, 8.3% for esophageal cancer, 1.3% for breast cancer, and 0.8% for Hodgkin lymphoma. Increased AF risk was associated with a higher PV maximum dose (d<sub>max</sub>) (sHR: 1.22; <em>P <</em> 0.001), larger left atrial volume (sHR: 1.01; <em>P =</em> 0.002), greater smoking history in pack-years (sHR: 1.01; <em>P =</em> 0.010), and higher MAFRS (sHR: 1.16; <em>P <</em> 0.001). PV d<sub>max</sub> remained a significant predictor of AF across different MAFRS subgroups (<em>P</em><sub>interaction</sub> = 0.11), and a PV d<sub>max</sub> >39.7 Gy was linked to a higher AF risk, even when stratified by MAFRS.</div></div><div><h3>Conclusions</h3><div>PV d<sub>max</sub> is a significant predictor of grade ≥3 AF regardless of underlying risk factors. These findings highlight the importance of cardiac substructures in radiation toxicity and suggest that various PV dose metrics should be further validated in clinical settings.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 6","pages":"Pages 935-945"},"PeriodicalIF":12.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711808/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.jaccao.2024.10.001
Tzu-Fei Wang MD, MPH
{"title":"The Rise and Fall of C-Reactive Protein","authors":"Tzu-Fei Wang MD, MPH","doi":"10.1016/j.jaccao.2024.10.001","DOIUrl":"10.1016/j.jaccao.2024.10.001","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 6","pages":"Pages 976-978"},"PeriodicalIF":12.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.jaccao.2024.10.008
Jacqueline B. Vo PhD, RN, MPH , Véronique L. Roger MD, MPH
{"title":"Cardiovascular Disease and Breast Cancer","authors":"Jacqueline B. Vo PhD, RN, MPH , Véronique L. Roger MD, MPH","doi":"10.1016/j.jaccao.2024.10.008","DOIUrl":"10.1016/j.jaccao.2024.10.008","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 6","pages":"Pages 904-906"},"PeriodicalIF":12.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711825/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.jaccao.2024.09.012
Darryl P. Leong MBBS, MPH, MBiostat, PhD , Avirup Guha MBBS, MPH , Alicia K. Morgans MD, MPH , Tamim Niazi MDCM , Jehonathan H. Pinthus MD, PhD
Cardiovascular disease is common in patients with prostate cancer and is a significant cause of death. Cardiovascular risk factors are frequent in this population and are often not addressed to thresholds recommended by cardiovascular practice guidelines. Androgen deprivation therapy reduces muscle strength and increases adiposity, increasing the risk for diabetes and hypertension, although its relationship with adverse cardiovascular events requires confirmation. Androgen receptor pathway inhibitors, including androgen receptor antagonists and cytochrome P450 17A1 inhibitors confer incremental risks for hypertension and cardiovascular events to androgen deprivation therapy. Lower cardiovascular risk with gonadotropin-releasing hormone antagonists compared with agonists requires confirmation in well-designed randomized trials.
{"title":"Cardiovascular Risk in Prostate Cancer","authors":"Darryl P. Leong MBBS, MPH, MBiostat, PhD , Avirup Guha MBBS, MPH , Alicia K. Morgans MD, MPH , Tamim Niazi MDCM , Jehonathan H. Pinthus MD, PhD","doi":"10.1016/j.jaccao.2024.09.012","DOIUrl":"10.1016/j.jaccao.2024.09.012","url":null,"abstract":"<div><div>Cardiovascular disease is common in patients with prostate cancer and is a significant cause of death. Cardiovascular risk factors are frequent in this population and are often not addressed to thresholds recommended by cardiovascular practice guidelines. Androgen deprivation therapy reduces muscle strength and increases adiposity, increasing the risk for diabetes and hypertension, although its relationship with adverse cardiovascular events requires confirmation. Androgen receptor pathway inhibitors, including androgen receptor antagonists and cytochrome P450 17A1 inhibitors confer incremental risks for hypertension and cardiovascular events to androgen deprivation therapy. Lower cardiovascular risk with gonadotropin-releasing hormone antagonists compared with agonists requires confirmation in well-designed randomized trials.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 6","pages":"Pages 835-846"},"PeriodicalIF":12.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711826/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.jaccao.2024.09.013
Wonyoung Jung MD, PhD, MSc , In Young Cho MD, MPH , Jinhyung Jung PhD , Mi Hee Cho MD , Hye Yeon Koo MD , Yong-Moon Mark Park MD, PhD , Kyungdo Han PhD , Dong Wook Shin MD, DrPH, MBA
Background
Cancer survivors face an elevated risk of cardiovascular disease, with physical inactivity after cancer treatment potentially worsening this risk.
Objectives
The aim of this study was to investigate the association between physical activity before and after a cancer diagnosis and the risk for heart disease.
Methods
A nationwide cohort of 269,943 cancer survivors (mean age 56.3, 45.7% men) was evaluated for physical activity adherence 2 years before and after diagnosis. The primary outcomes were the incidence of myocardial infarction (MI), heart failure (HF), and atrial fibrillation. Subdistribution HRs (sHRs) and 95% CIs were calculated using Gray’s method, accounting for death as a competing risk.
Results
Over a follow-up period of 1,111,329.28 person-years, compared with those who remained inactive, persistent physical activity was associated with a 20% reduction in MI risk (sHR: 0.80; 95% CI: 0.70-0.91) and a 16% reduction risk in HF risk (sHR: 0.84; 95% CI: 0.78-0.90). Initiating physical activity after a cancer diagnosis was linked to an 11% lower risk for MI (sHR: 0.89; 95% CI: 0.79-0.99) and a 13% lower risk for HF (sHR: 0.87; 95% CI: 0.82-0.93). Being active only before diagnosis was associated with a 20% lower risk for MI (sHR: 0.80; 95% CI: 0.71-0.91) and a 6% lower risk for HF (sHR: 0.94; 95% CI: 0.88-1.00). No association was observed between physical activity and atrial fibrillation risk. Associations varied by primary cancer site.
Conclusions
These findings underscore the importance of maintaining physical activity for cardiovascular health in cancer survivors and suggest that physical activity before a diagnosis may offer enduring protection against ischemic heart disease and cardiac dysfunction.
{"title":"Changes in Physical Activity and Cardiovascular Disease Risk in Cancer Survivors","authors":"Wonyoung Jung MD, PhD, MSc , In Young Cho MD, MPH , Jinhyung Jung PhD , Mi Hee Cho MD , Hye Yeon Koo MD , Yong-Moon Mark Park MD, PhD , Kyungdo Han PhD , Dong Wook Shin MD, DrPH, MBA","doi":"10.1016/j.jaccao.2024.09.013","DOIUrl":"10.1016/j.jaccao.2024.09.013","url":null,"abstract":"<div><h3>Background</h3><div>Cancer survivors face an elevated risk of cardiovascular disease, with physical inactivity after cancer treatment potentially worsening this risk.</div></div><div><h3>Objectives</h3><div>The aim of this study was to investigate the association between physical activity before and after a cancer diagnosis and the risk for heart disease.</div></div><div><h3>Methods</h3><div>A nationwide cohort of 269,943 cancer survivors (mean age 56.3, 45.7% men) was evaluated for physical activity adherence 2 years before and after diagnosis. The primary outcomes were the incidence of myocardial infarction (MI), heart failure (HF), and atrial fibrillation. Subdistribution HRs (sHRs) and 95% CIs were calculated using Gray’s method, accounting for death as a competing risk.</div></div><div><h3>Results</h3><div>Over a follow-up period of 1,111,329.28 person-years, compared with those who remained inactive, persistent physical activity was associated with a 20% reduction in MI risk (sHR: 0.80; 95% CI: 0.70-0.91) and a 16% reduction risk in HF risk (sHR: 0.84; 95% CI: 0.78-0.90). Initiating physical activity after a cancer diagnosis was linked to an 11% lower risk for MI (sHR: 0.89; 95% CI: 0.79-0.99) and a 13% lower risk for HF (sHR: 0.87; 95% CI: 0.82-0.93). Being active only before diagnosis was associated with a 20% lower risk for MI (sHR: 0.80; 95% CI: 0.71-0.91) and a 6% lower risk for HF (sHR: 0.94; 95% CI: 0.88-1.00). No association was observed between physical activity and atrial fibrillation risk. Associations varied by primary cancer site.</div></div><div><h3>Conclusions</h3><div>These findings underscore the importance of maintaining physical activity for cardiovascular health in cancer survivors and suggest that physical activity before a diagnosis may offer enduring protection against ischemic heart disease and cardiac dysfunction.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 6","pages":"Pages 879-889"},"PeriodicalIF":12.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711819/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01DOI: 10.1016/j.jaccao.2024.08.002
Steven Petrow
{"title":"Cancer Survivors and Cardiovascular Risk: What Patients Should Know From the Perspective of Another Survivor","authors":"Steven Petrow","doi":"10.1016/j.jaccao.2024.08.002","DOIUrl":"10.1016/j.jaccao.2024.08.002","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 5","pages":"Pages 808-810"},"PeriodicalIF":12.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142437694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01DOI: 10.1016/j.jaccao.2024.07.011
Darryl P. Leong MBBS, MPH, MBiostat, PhD , Vincent Fradet MD, PhD , Tamim Niazi MD , Joseph B. Selvanayagam MBBS, DPhil , Robert Sabbagh MD, MSc , Celestia S. Higano MD , Steven Agapay BSc , Sumathy Rangarajan MSc , Rajibul Mian PhD , Carlos A.K. Nakashima MD, PhD , Negareh Mousavi MD , Ian Brown MD , Felipe H. Valle MD, PhD , Luke T. Lavallée MDCM, MSc , Bobby Shayegan MD , Kelvin K.H. Ng MBBS , Darin D. Gopaul MD , Germano D. Cavalli MD , Sonia Saavedra MD , Jose P. Lopez-Lopez MD , Jehonathan Pinthus MD, PhD
Background
There are limited data on the physical effects of androgen deprivation therapy (ADT) for prostate cancer (PC), and on the relationships of such measures of adiposity and strength to cardiovascular outcomes.
Objectives
The primary objective of this study was to evaluate the relationships of measures of adiposity and strength to cardiovascular outcomes (cardiovascular death, myocardial infarction, stroke, heart failure, arterial revascularization, peripheral arterial disease, and venous thromboembolism) in patients with PC. A secondary objective was to characterize the relationships between ADT use and 12-month changes in these physical measures.
Methods
This international, prospective cohort study included 3,967 patients with PC diagnosed in the prior 12 months or being treated with ADT for the first time. Median follow-up duration was 2.3 years.
Results
Participants’ mean age was 68.5 years, and 1,731 (43.6%) were exposed to ADT. ADT was associated with a 1.6% increase in weight, a 2.2% increase in waist circumference, a 1.6% increase in hip circumference, a 0.1% increase in waist-to-hip ratio, a 27.4% reduction in handgrip strength, and a 0.1% decrease in gait speed. High waist circumference and low handgrip strength were associated with adverse cardiovascular outcomes. Adjusting for age, education, race, tobacco and alcohol use, physical activity, cardiovascular disease, glomerular filtration rate, and ADT use, waist circumference above the highest quartile (110 cm) and handgrip strength below the lowest quartile (29.5 kg) were associated with higher likelihoods of a future cardiovascular event, with respective HRs of 1.40 (95% CI: 1.03-1.90; P = 0.029) and 1.59 (95% CI: 1.14-2.22; P = 0.006).
Conclusions
ADT was associated with increased adiposity and reduced strength over 12-month follow-up. High waist circumference and low baseline strength were associated with future adverse cardiovascular outcomes.
{"title":"Adiposity and Muscle Strength in Men With Prostate Cancer and Cardiovascular Outcomes","authors":"Darryl P. Leong MBBS, MPH, MBiostat, PhD , Vincent Fradet MD, PhD , Tamim Niazi MD , Joseph B. Selvanayagam MBBS, DPhil , Robert Sabbagh MD, MSc , Celestia S. Higano MD , Steven Agapay BSc , Sumathy Rangarajan MSc , Rajibul Mian PhD , Carlos A.K. Nakashima MD, PhD , Negareh Mousavi MD , Ian Brown MD , Felipe H. Valle MD, PhD , Luke T. Lavallée MDCM, MSc , Bobby Shayegan MD , Kelvin K.H. Ng MBBS , Darin D. Gopaul MD , Germano D. Cavalli MD , Sonia Saavedra MD , Jose P. Lopez-Lopez MD , Jehonathan Pinthus MD, PhD","doi":"10.1016/j.jaccao.2024.07.011","DOIUrl":"10.1016/j.jaccao.2024.07.011","url":null,"abstract":"<div><h3>Background</h3><div>There are limited data on the physical effects of androgen deprivation therapy (ADT) for prostate cancer (PC), and on the relationships of such measures of adiposity and strength to cardiovascular outcomes.</div></div><div><h3>Objectives</h3><div>The primary objective of this study was to evaluate the relationships of measures of adiposity and strength to cardiovascular outcomes (cardiovascular death, myocardial infarction, stroke, heart failure, arterial revascularization, peripheral arterial disease, and venous thromboembolism) in patients with PC. A secondary objective was to characterize the relationships between ADT use and 12-month changes in these physical measures.</div></div><div><h3>Methods</h3><div>This international, prospective cohort study included 3,967 patients with PC diagnosed in the prior 12 months or being treated with ADT for the first time. Median follow-up duration was 2.3 years.</div></div><div><h3>Results</h3><div>Participants’ mean age was 68.5 years, and 1,731 (43.6%) were exposed to ADT. ADT was associated with a 1.6% increase in weight, a 2.2% increase in waist circumference, a 1.6% increase in hip circumference, a 0.1% increase in waist-to-hip ratio, a 27.4% reduction in handgrip strength, and a 0.1% decrease in gait speed. High waist circumference and low handgrip strength were associated with adverse cardiovascular outcomes. Adjusting for age, education, race, tobacco and alcohol use, physical activity, cardiovascular disease, glomerular filtration rate, and ADT use, waist circumference above the highest quartile (110 cm) and handgrip strength below the lowest quartile (29.5 kg) were associated with higher likelihoods of a future cardiovascular event, with respective HRs of 1.40 (95% CI: 1.03-1.90; <em>P</em> = 0.029) and 1.59 (95% CI: 1.14-2.22; <em>P</em> = 0.006).</div></div><div><h3>Conclusions</h3><div>ADT was associated with increased adiposity and reduced strength over 12-month follow-up. High waist circumference and low baseline strength were associated with future adverse cardiovascular outcomes.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 5","pages":"Pages 761-771"},"PeriodicalIF":12.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142438298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01DOI: 10.1016/j.jaccao.2024.07.015
Saro H. Armenian DO, MPH , Melissa M. Hudson MD , Lanie Lindenfeld MA , Sitong Chen MS , Eric J. Chow MD, MPH , Steven Colan MD , Meagan Echevarria MPH , F. Lennie Wong PhD , Ming Hui Chen MD , Smita Bhatia MD, MPH
{"title":"Carvedilol to Improve Cardiac Remodeling in Anthracycline-Exposed Childhood Cancer Survivors","authors":"Saro H. Armenian DO, MPH , Melissa M. Hudson MD , Lanie Lindenfeld MA , Sitong Chen MS , Eric J. Chow MD, MPH , Steven Colan MD , Meagan Echevarria MPH , F. Lennie Wong PhD , Ming Hui Chen MD , Smita Bhatia MD, MPH","doi":"10.1016/j.jaccao.2024.07.015","DOIUrl":"10.1016/j.jaccao.2024.07.015","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 5","pages":"Pages 791-793"},"PeriodicalIF":12.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142438302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号